PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24845641-5	2014	Mice with OIR were injected intraperitoneally with the PPARalpha agonist fenofibric acid (FA) or with adenovirus expressing PPARalpha (Ad-PPARalpha).	fenofibric acid	73-88	peroxisome proliferator activated receptor alpha	Mus musculus	55-64	
25516156-9	2015	Fenofibric acid, the active metabolite of the PPARalpha agonist fenofibrate, was detected in liver, plasma, and brain after 1 or 8 days of oral treatment.	fenofibric acid	0-15	peroxisome proliferator activated receptor alpha	Mus musculus	46-55	
19534718-6	2009	The EC monolayer permeability increase induced by 4 h of OGD was significantly restricted after treatment with the PPAR-alpha agonist fenofibric acid (FA) 24 h before or at the onset of OGD.	fenofibric acid	134-149	peroxisome proliferator activated receptor alpha	Mus musculus	115-125	
24825105-10	2014	Nuclear hypoxia-inducible factor-alpha (HIF-1alpha) and nicotine adenine dinucleotide phosphate oxidase-4 (Nox 4) were increased in OIR retinas and downregulated by Feno-FA in WT but not in PPARalpha(-/-) mice.	fenofibric acid	165-172	peroxisome proliferator activated receptor alpha	Mus musculus	190-199	
21888945-6	2012	When administered in combination with a PPARalpha agonist (fenofibric acid) but not with a PPARgamma agonist (pioglitazone), BMP-4 enhanced osteoblast differentiation through the activity of PPARalpha.	fenofibric acid	59-74	peroxisome proliferator activated receptor alpha	Mus musculus	191-200	
31078963-3	2019	However, fenofibrate does not cross the blood brain barrier and is quickly processed by blood and tissue esterases to form the PPARalpha agonist fenofibric acid, which is practically ineffective effective in triggering cancer cell death.	fenofibric acid	145-160	peroxisome proliferator activated receptor alpha	Mus musculus	127-136	
30765336-5	2019	In vitro, fenofibric acid (FFA) rescued high glucose-induced (25 mmol/L) impairment of endothelial cell migration, tubulogenesis, and survival in a PPARalpha-independent manner.	fenofibric acid	10-25	peroxisome proliferator activated receptor alpha	Mus musculus	148-157	
30765336-5	2019	In vitro, fenofibric acid (FFA) rescued high glucose-induced (25 mmol/L) impairment of endothelial cell migration, tubulogenesis, and survival in a PPARalpha-independent manner.	fenofibric acid	27-30	peroxisome proliferator activated receptor alpha	Mus musculus	148-157	
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	56-71	peroxisome proliferator activated receptor alpha	Mus musculus	85-133	
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	56-71	peroxisome proliferator activated receptor alpha	Mus musculus	135-144	
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	56-71	peroxisome proliferator activated receptor alpha	Mus musculus	305-314	
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	73-80	peroxisome proliferator activated receptor alpha	Mus musculus	135-144	
28980001-1	2017	Purpose: This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPARalpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPARalpha dependent.	fenofibric acid	73-80	peroxisome proliferator activated receptor alpha	Mus musculus	305-314	
28980001-10	2017	Furthermore, Pparalpha-/- mice developed more severe CNV compared with WT mice, and PPARalpha knockout abolished the beneficial effects of Feno-FA on CNV.	fenofibric acid	139-146	peroxisome proliferator activated receptor alpha	Mus musculus	84-93	
28980001-11	2017	Conclusions: Feno-FA has therapeutic effects on ocular NV in models recapitulating neovascular AMD through a PPARalpha-dependent mechanism.	fenofibric acid	13-20	peroxisome proliferator activated receptor alpha	Mus musculus	109-118	
29182629-11	2017	Pioglitazone (PPARgamma-specific), tesaglitazar (PPARgamma/alpha-specific), and fenofibric acid (PPARalpha-specific) all provided >90% protection from gentamicin toxicity by regulation of overlapping subsets of genes controlling ROS detoxification.	fenofibric acid	80-95	peroxisome proliferator activated receptor alpha	Mus musculus	97-106